ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:ACAD
- CUSIP: N/A
- Web: www.acadia-pharm.com
Capitalization:- Market Cap: $3.7 billion
- Outstanding Shares: 122,046,000
Average Prices:- 50 Day Moving Avg: $27.92
- 200 Day Moving Avg: $32.16
- 52 Week Range: $20.68 - $40.83
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -14.79
- P/E Growth: -0.37
Sales & Book Value:- Annual Revenue: $32.61 million
- Price / Sales: 113.44
- Book Value: $3.75 per share
- Price / Book: 8.08
Profitability:- EBIDTA: ($309,030,000.00)
- Net Margins: -948.93%
- Return on Equity: -63.07%
- Return on Assets: -58.40%
Debt:- Current Ratio: 10.82%
- Quick Ratio: 10.74%
Misc:- Average Volume: 1.58 million shs.
- Beta: 3.93
- Short Ratio: 12.66
Frequently Asked Questions for ACADIA Pharmaceuticals (NASDAQ:ACAD)
What is ACADIA Pharmaceuticals' stock symbol?
ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."
How were ACADIA Pharmaceuticals' earnings last quarter?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.72) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.73) by $0.01. The company earned $15.30 million during the quarter, compared to analysts' expectations of $15.17 million. ACADIA Pharmaceuticals had a negative return on equity of 63.07% and a negative net margin of 948.93%. During the same quarter in the previous year, the business earned ($0.45) earnings per share. View ACADIA Pharmaceuticals' Earnings History.
When will ACADIA Pharmaceuticals make its next earnings announcement?
Where is ACADIA Pharmaceuticals' stock going? Where will ACADIA Pharmaceuticals' stock price be in 2017?
14 analysts have issued 1-year price objectives for ACADIA Pharmaceuticals' stock. Their predictions range from $25.00 to $60.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $43.00 in the next year. View Analyst Ratings for ACADIA Pharmaceuticals.
What are analysts saying about ACADIA Pharmaceuticals stock?
Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (7/17/2017)
- 2. Needham & Company LLC analysts commented, "Acadia reported $11.9M in 4Q16 Nuplazid sales, above our $9.0M estimate. Mgmt noted steady growth in number of prescribers, repeat prescribers, and new patients. Company also announced plan to expand sales force by 20 reps to address long-term care opportunity. There are no immediate plans to provide 2017 sales guidance. We believe stock is attractive given Nuplazid launch trajectory and likelihood for label expansion in long-term. Stock likely to be driven by sales in 2017 and Phase 2/3 results in other indications in 2018/ 2019. Acadia may be an attractive M&A target. BUY." (3/1/2017)
Who are some of ACADIA Pharmaceuticals' key competitors?
Some companies that are related to ACADIA Pharmaceuticals include Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), ICON PLC (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Sage Therapeutics (SAGE), INC Research Holdings (INCR), Intrexon Corporation (XON), Ligand Pharmaceuticals Incorporated (LGND) and Ironwood Pharmaceuticals (IRWD).
Who are ACADIA Pharmaceuticals' key executives?
ACADIA Pharmaceuticals' management team includes the folowing people:
- Stephen R. Biggar M.D. Ph.D., Chairman of the Board
- Stephen R. Davis, President, Chief Executive Officer, Director
- Todd S. Young, Executive Vice President, Chief Financial Officer
- Glenn F. Baity, Executive Vice President, General Counsel, Secretary
- Srdjan Stankovic M.D., Executive Vice President, Head - Research and Development
- Michael J. Yang, Executive Vice President, Chief Commercial Officer
- Edmund P. Harrigan M.D., Director
- Julian C. Baker, Independent Director
- Laura A. Brege, Independent Director
- James M. Daly, Independent Director
Who owns ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
BAKER BROS. ADVISORS LP
(22.10%), Harvey Capital Management Inc. (0.19%), Handelsbanken Fonder AB (0.15%), Handelsinvest Investeringsforvaltning (0.05%), Creative Planning (0.02%) and Aperio Group LLC (0.01%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Edmund Harrigan, Glenn Baity, Leslie L Iversen, LP 14159 and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.
Who sold ACADIA Pharmaceuticals stock? Who is selling ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Aperio Group LLC and Hollencrest Securities LLC. Company insiders that have sold ACADIA Pharmaceuticals stock in the last year include Glenn Baity and Terrence O Moore. View Insider Buying and Selling for ACADIA Pharmaceuticals.
Who bought ACADIA Pharmaceuticals stock? Who is buying ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Handelsinvest Investeringsforvaltning, Handelsbanken Fonder AB, Legato Capital Management LLC, Harvey Capital Management Inc. and Creative Planning. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Edmund Harrigan and LP 14159. View Insider Buying and Selling for ACADIA Pharmaceuticals.
How do I buy ACADIA Pharmaceuticals stock?
Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ACADIA Pharmaceuticals' stock price today?
One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $30.31.
MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 10 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.71) |
| Consensus Price Target: | $43.00 (41.87% upside) |
Analysts' Ratings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/22/2017 | Rodman & Renshaw | Reiterated Rating | Buy | $60.00 | Low |  |
| 5/10/2017 | HC Wainwright | Reiterated Rating | Buy | | Low | |
| 4/12/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $47.00 | Low | |
| 4/5/2017 | Needham & Company LLC | Reiterated Rating | Buy | $49.00 | Low | |
| 2/7/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $44.00 | N/A | |
| 2/2/2017 | Ladenburg Thalmann Financial Services | Initiated Coverage | Buy -> Buy | $49.00 -> $48.00 | N/A | |
| 1/24/2017 | Cowen and Company | Reiterated Rating | Outperform | $42.00 | N/A | |
| 1/11/2017 | J P Morgan Chase & Co | Reiterated Rating | Buy | | N/A | |
| 12/28/2016 | Leerink Swann | Reiterated Rating | Market Perform | $29.00 | N/A | |
| 11/11/2016 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral | $28.00 | N/A | |
| 11/8/2016 | Bank of America Corporation | Upgrade | Neutral -> Buy | $35.00 | N/A | |
| 10/19/2016 | Roth Capital | Reiterated Rating | Neutral | $25.00 | N/A | |
| 8/10/2016 | JMP Securities | Reiterated Rating | Buy | $45.00 | N/A | |
| 8/5/2016 | Aegis | Downgrade | Buy -> Hold | $54.00 -> $41.00 | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)Earnings History by Quarter for ACADIA Pharmaceuticals (NASDAQ ACAD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | ($0.72) | | | | | N/A | |
| 5/9/2017 | Q1 2017 | ($0.73) | ($0.72) | $15.17 million | $15.30 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.65) | ($0.65) | $9.05 million | $12.00 million | View | Listen | |
| 11/7/2016 | Q316 | ($0.56) | ($0.61) | $2.90 million | $5.30 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.49) | ($0.63) | $0.71 million | $0.97 million | View | Listen | |
| 5/5/2016 | Q116 | ($0.42) | ($0.45) | $0.22 million | | View | Listen | |
| 2/29/2016 | Q415 | ($0.38) | ($0.45) | | $0.02 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.40) | ($0.39) | $0.05 million | $0.04 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.33) | ($0.39) | $0.06 million | | View | Listen | |
| 5/7/2015 | Q115 | ($0.25) | ($0.40) | $0.09 million | | View | Listen | |
| 2/26/2015 | Q414 | ($0.26) | ($0.28) | $0.08 million | $0.05 million | View | Listen | |
| 11/10/2014 | Q3 | ($0.12) | ($0.25) | | $0.02 million | View | Listen | |
| 8/5/2014 | Q2 | ($0.17) | ($0.22) | $0.10 million | $0.03 million | View | Listen | |
| 5/6/2014 | Q1 | ($0.13) | ($0.19) | $0.50 million | $0.03 million | View | Listen | |
| 2/27/2014 | Q4 | ($0.14) | ($0.13) | | | View | Listen | |
| 8/6/2013 | Q2 2013 | ($0.09) | ($0.11) | $0.45 million | $451.00 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.08) | ($0.08) | $0.45 million | $0.42 million | View | Listen | |
| 11/5/2012 | Q312 | ($0.09) | ($0.04) | $1.90 million | $3.50 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)2017 EPS Consensus Estimate: ($2.37)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.75) | ($0.53) | ($0.64) |
| Q2 2017 | 2 | ($0.71) | ($0.48) | ($0.60) |
| Q3 2017 | 2 | ($0.72) | ($0.44) | ($0.58) |
| Q4 2017 | 2 | ($0.71) | ($0.39) | ($0.55) |
(Data provided by Zacks Investment Research)
Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ACADIA Pharmaceuticals (NASDAQ:ACAD)Insider Ownership Percentage: 22.25%
Institutional Ownership Percentage: 97.18%
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/20/2017 | Glenn Baity | EVP | Sell | 38,097 | $30.00 | $1,142,910.00 | |
| 6/22/2017 | Glenn Baity | EVP | Sell | 1,903 | $30.00 | $57,090.00 | |
| 2/16/2017 | Terrence O. Moore | EVP | Sell | 157,540 | $39.77 | $6,265,365.80 | |
| 12/27/2016 | Glenn Baity | EVP | Sell | 9,800 | $30.46 | $298,508.00 | |
| 12/20/2016 | Glenn Baity | EVP | Sell | 10,000 | $30.00 | $300,000.00 | |
| 8/16/2016 | Edmund Harrigan | Director | Buy | 1,000 | $32.97 | $32,970.00 | |
| 8/10/2016 | Bros. Advisors Lp Baker | Director | Buy | 1,303,030 | $33.00 | $42,999,990.00 | |
| 7/12/2016 | Glenn Baity | EVP | Sell | 16,000 | $35.00 | $560,000.00 | |
| 7/11/2016 | Glenn Baity | EVP | Sell | 4,057 | $35.00 | $141,995.00 | |
| 4/18/2016 | Leslie L Iversen | Director | Sell | 33,697 | $33.53 | $1,129,860.41 | |
| 4/1/2016 | Bros. Advisors Lp Baker | Director | Buy | 1,449,090 | $27.08 | $39,241,357.20 | |
| 1/7/2016 | L.P. 14159 | Director | Buy | 2,586,206 | $29.00 | $74,999,974.00 | |
| 11/11/2015 | Leslie L. Iversen | Director | Sell | 30,000 | $36.01 | $1,080,300.00 | |
| 1/15/2015 | Michael T Borer | Director | Sell | 27,973 | $33.02 | $923,668.46 | |
| 1/14/2015 | Uli Hacksell | CEO | Sell | 30,000 | $33.98 | $1,019,400.00 | |
| 12/15/2014 | Mary Ann Gray | Director | Sell | 12,250 | $31.74 | $388,815.00 | |
| 12/15/2014 | Uli Hacksell | CEO | Sell | 30,000 | $31.00 | $930,000.00 | |
| 11/26/2014 | Michael T Borer | Director | Sell | 15,000 | $30.05 | $450,750.00 | |
| 11/26/2014 | Roger Mills | CMO | Sell | 25,000 | $30.09 | $752,250.00 | |
| 11/24/2014 | Uli Hacksell | CEO | Sell | 30,000 | $29.28 | $878,400.00 | |
| 11/21/2014 | William Mcdowall Wells | Director | Sell | 5,810 | $29.00 | $168,490.00 | |
| 10/8/2014 | Uli Hacksell | CEO | Sell | 30,000 | $24.15 | $724,500.00 | |
| 9/15/2014 | Laura Brege | Director | Sell | 10,000 | $28.07 | $280,700.00 | |
| 9/12/2014 | William Mcdowall Wells | Director | Sell | 9,190 | $29.15 | $267,888.50 | |
| 9/10/2014 | Uli Hacksell | CEO | Sell | 30,000 | $27.36 | $820,800.00 | |
| 8/15/2014 | Uli Hacksell | CEO | Sell | 15,000 | $22.89 | $343,350.00 | |
| 7/14/2014 | Uli Hacksell | CEO | Sell | 20,000 | $22.22 | $444,400.00 | |
| 6/16/2014 | Uli Hacksell | CEO | Sell | 20,000 | $23.10 | $462,000.00 | |
| 6/9/2014 | William Mcdowall Wells | Director | Sell | 15,000 | $23.03 | $345,450.00 | |
| 5/1/2014 | Torsten Rasmussen | Director | Sell | 32,857 | $20.03 | $658,125.71 | |
| 4/15/2014 | Uli Hacksell | CEO | Sell | 25,000 | $17.75 | $443,750.00 | |
| 4/4/2014 | Thomas Aasen | CFO | Sell | 15,000 | $22.48 | $337,200.00 | |
| 4/4/2014 | Torsten Rasmussen | Director | Sell | 30,000 | $21.98 | $659,400.00 | |
| 3/5/2014 | Bros. Advisors Lp Baker | Director | Buy | 526,316 | $28.50 | $15,000,006.00 | |
| 2/26/2014 | Glenn Baity | VP | Sell | 42,000 | $30.28 | $1,271,760.00 | |
| 11/1/2013 | Torsten Rasmussen | Director | Sell | 37,692 | $23.00 | $866,916.00 | |
| 11/1/2013 | Uli Hacksell | CEO | Sell | 15,000 | $23.24 | $348,600.00 | |
| 10/10/2013 | Laura Brege | Director | Sell | 10,000 | $21.63 | $216,300.00 | |
| 10/1/2013 | Thomas H Aasen | CFO | Sell | 30,000 | $27.87 | $836,100.00 | |
| 9/20/2013 | Roger Mills | CMO | Sell | 35,965 | $25.01 | $899,484.65 | |
| 9/12/2013 | Lester Ph Kaplan | Director | Sell | 66,356 | $22.90 | $1,519,552.40 | |
| 9/10/2013 | Laura Brege | Director | Sell | 46,153 | $22.80 | $1,052,288.40 | |
| 9/3/2013 | Torsten Rasmussen | Director | Sell | 40,000 | $20.28 | $811,200.00 | |
| 8/26/2013 | Mary Ann Gray | Director | Sell | 15,000 | $20.68 | $310,200.00 | |
| 8/13/2013 | Thomas Aasen | CFO | Sell | 60,000 | $20.15 | $1,209,000.00 | |
| 8/13/2013 | Uli Hacksell | CEO | Sell | 52,771 | $20.14 | $1,062,807.94 | |
| 6/5/2013 | Felix Baker | Director | Buy | 2,340,314 | $14.34 | $33,560,102.76 | |
| 5/15/2013 | Felix Baker | Director | Buy | 1,993,000 | $12.50 | $24,912,500.00 | |
| 4/12/2013 | Glenn Baity | VP | Sell | 60,000 | $12.42 | $745,200.00 | |
| 4/11/2013 | Thomas H Aasen | CFO | Sell | 40,000 | $11.06 | $442,400.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Latest Headlines for ACADIA Pharmaceuticals (NASDAQ:ACAD)
| Source: |
|
| Date | Headline |
|---|
 | ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Announce Quarterly Sales of $19.59 Million
www.americanbankingnews.com - July 23 at 9:18 AM |
| Glenn Baity Sells 38,097 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock
www.americanbankingnews.com - July 21 at 7:11 PM |
 | 7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods - TheStreet.com
www.thestreet.com - July 21 at 4:39 PM |
 | 7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods
finance.yahoo.com - July 21 at 4:39 PM |
| ETFs with exposure to ACADIA Pharmaceuticals, Inc. : July 21, 2017
finance.yahoo.com - July 21 at 4:39 PM |
| Brokerages Expect ACADIA Pharmaceuticals Inc. (ACAD) Will Announce Earnings of -$0.71 Per Share
www.americanbankingnews.com - July 21 at 2:20 PM |
 | Today's Research Report Coverage on Biotech Stocks -- ACADIA Pharma, Aduro BioTech, Agios Pharma, and AveXis - PR Newswire (press release)
www.prnewswire.com - July 20 at 3:29 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 17 at 9:40 PM |
| Today's Research Reports on Stocks to Watch: ACADIA Pharmaceuticals Inc. and Mylan N.V.
finance.yahoo.com - July 13 at 3:47 PM |
| ACADIA Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACAD) : July 12, 2017
finance.yahoo.com - July 12 at 3:44 PM |
| ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : July 11, 2017
finance.yahoo.com - July 11 at 4:26 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 11 at 2:10 PM |
 | Faruqi & Faruqi, LLP Announces Proposed Settlement of Acadia Securities Litigation
www.bizjournals.com - July 11 at 1:30 AM |
| Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half - TheStreet.com
www.thestreet.com - July 10 at 3:26 PM |
| ETFs with exposure to ACADIA Pharmaceuticals, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 3:26 PM |
 | Acadia: Order For Central Nervous Systems In Need - Seeking Alpha
seekingalpha.com - July 5 at 3:34 PM |
| Acadia Has A Steep Path Ahead - Seeking Alpha
seekingalpha.com - July 5 at 3:34 PM |
| Analysts Expect ACADIA Pharmaceuticals Inc. (ACAD) Will Announce Quarterly Sales of $19.59 Million
www.americanbankingnews.com - June 29 at 11:32 AM |
| ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : June 27, 2017
finance.yahoo.com - June 27 at 3:21 PM |
| ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 27, 2017
finance.yahoo.com - June 27 at 3:21 PM |
| Zacks: Analysts Anticipate ACADIA Pharmaceuticals Inc. (ACAD) Will Post Earnings of -$0.71 Per Share
www.americanbankingnews.com - June 27 at 10:32 AM |
| ACADIA Pharmaceuticals Inc. (ACAD) EVP Glenn Baity Sells 1,903 Shares
www.americanbankingnews.com - June 26 at 7:39 PM |
 | Minerva On Track to Initiate Phase III Schizophrenia Study - Nasdaq
www.nasdaq.com - June 26 at 3:35 PM |
| ACADIA: Is It The Right Time To Buy? - ACADIA Pharmaceuticals Inc ... - Seeking Alpha
seekingalpha.com - June 26 at 3:35 PM |
 | Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma - Benzinga
www.benzinga.com - June 22 at 1:07 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) Raised to Sell at BidaskClub
www.americanbankingnews.com - June 21 at 10:02 PM |
| 3 Value Stocks You Haven't Thought Of
finance.yahoo.com - June 19 at 3:17 PM |
| ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 3:32 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 16 at 12:50 PM |
| ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 6:18 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) Expected to Post Quarterly Sales of $18.44 Million
www.americanbankingnews.com - June 3 at 9:48 AM |
| ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 3:41 PM |
| Zacks: Analysts Anticipate ACADIA Pharmaceuticals Inc. (ACAD) Will Announce Earnings of -$0.71 Per Share
www.americanbankingnews.com - June 1 at 8:10 AM |
| ACADIA Pharmaceuticals Draws Value From Nuplazid Revenue Stream
seekingalpha.com - May 31 at 11:24 AM |
| ACADIA Pharmaceuticals (ACAD) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 24 at 3:17 PM |
| Positive Clinical Results Ahead For Acadia Pharmaceuticals - Seeking Alpha
seekingalpha.com - May 23 at 5:31 AM |
| ACADIA Pharmaceuticals Inc. (ACAD) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 22 at 12:25 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) Stock Rating Reaffirmed by Rodman & Renshaw
www.americanbankingnews.com - May 22 at 10:54 AM |
| Longwood Capital Partners LLC Buys ACADIA Pharmaceuticals Inc, Viveve Medical Inc, Biocryst ... - Nasdaq
www.nasdaq.com - May 16 at 5:40 AM |
| ACADIA Pharmaceuticals Inc. (ACAD) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - May 12 at 10:06 PM |
| Acadia Pharmaceuticals: Patience Will Be Rewarded - Seeking Alpha
seekingalpha.com - May 12 at 3:34 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) to Post Q2 2017 Earnings of ($0.71) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 12 at 10:58 AM |
| ACADIA Pharmaceuticals Inc. (ACAD) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - May 11 at 7:36 AM |
| Edited Transcript of ACAD earnings conference call or presentation 9-May-17 9:00pm GMT
finance.yahoo.com - May 10 at 8:27 PM |
| Oversold Conditions For Acadia Pharmaceuticals (ACAD) - Nasdaq
www.nasdaq.com - May 10 at 3:25 PM |
| The Acadia Sell-off Is Overdone
finance.yahoo.com - May 10 at 3:25 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Quarterly Sales of $18.39 Million
www.americanbankingnews.com - May 10 at 11:54 AM |
| ACADIA Pharmaceuticals Inc. (ACAD) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 10 at 12:36 AM |
 | BRIEF-Acadia Pharmaceuticals reports Q1 revenue $15.3 million
www.reuters.com - May 9 at 8:19 PM |
 | 10-Q: ACADIA PHARMACEUTICALS INC
www.marketwatch.com - May 9 at 8:19 PM |
ACADIA Pharmaceuticals (ACAD) Chart for Monday, July, 24, 2017
